Pharmaceutical provisions of the FDA Modernization Act of 1997: one year and counting

被引:2
|
作者
Binder, GM [1 ]
机构
[1] Amgen, Thousand Oaks, CA 91320 USA
关键词
D O I
10.1016/S0958-1669(99)80054-8
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The FDA Modernization Act of 1997 represents a notable public policy achievement that was conceived not out of crisis, but rather out of a shared commitment that the FDA can both protect patient health (by assuring drugs are safe and effective) and promote public health (by being given additional resources and new procedural efficiencies to accelerate the review of applications for new medicines). The FDA is conscientiously implementing this important new law, but there are areas where more work is required. On balance, the prospects are that this law will help usher in a much improved era for patients.
引用
收藏
页码:303 / 306
页数:4
相关论文
共 50 条